82P Stock Overview
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Pacira BioSciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$24.80 |
| 52 Week High | US$42.80 |
| 52 Week Low | US$23.80 |
| Beta | 0.75 |
| 1 Month Change | -7.46% |
| 3 Month Change | -13.29% |
| 1 Year Change | -39.51% |
| 3 Year Change | -53.64% |
| 5 Year Change | -30.03% |
| Change since IPO | 418.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| 82P | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -3.9% | -2.9% | -2.5% |
| 1Y | -39.5% | -31.3% | -0.4% |
Return vs Industry: 82P underperformed the German Pharmaceuticals industry which returned -31.3% over the past year.
Return vs Market: 82P underperformed the German Market which returned -0.4% over the past year.
Price Volatility
| 82P volatility | |
|---|---|
| 82P Average Weekly Movement | 4.8% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 82P's share price has been volatile over the past 3 months.
Volatility Over Time: 82P's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 712 | Frank Lee | www.pacira.com |
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product.
Pacira BioSciences, Inc. Fundamentals Summary
| 82P fundamental statistics | |
|---|---|
| Market cap | €1.17b |
| Earnings (TTM) | €39.42m |
| Revenue (TTM) | €634.14m |
28.9x
P/E Ratio1.8x
P/S RatioIs 82P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 82P income statement (TTM) | |
|---|---|
| Revenue | US$674.98m |
| Cost of Revenue | US$260.93m |
| Gross Profit | US$414.05m |
| Other Expenses | US$372.10m |
| Earnings | US$41.96m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.90 |
| Gross Margin | 61.34% |
| Net Profit Margin | 6.22% |
| Debt/Equity Ratio | 60.0% |
How did 82P perform over the long term?
See historical performance and comparison